Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 6, 2016, Pages 1406-1417

  Gee, Julianne ^a   Weinbaum, Cindy ^a   Sukumaran, Lakshmi ^a   Markowitz, Lauri E ^b  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

AUTOIMMUNE DISEASE; COMPLEX REGIONAL PAIN SYNDROME; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; ICD-9; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; PAPILLOMAVIRUS INFECTION; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PREGNANCY; PREMATURE OVARIAN FAILURE; REVIEW; UNITED STATES; VACCINATION; VENOUS THROMBOEMBOLISM; WART VIRUS; CHEMICALLY INDUCED; DRUG SURVEILLANCE PROGRAM; EPIDEMIOLOGICAL MONITORING; SYNCOPE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; EPIDEMIOLOGICAL MONITORING; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; SYNCOPE; UNITED STATES;

EID: 84976331389     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1168952     Document Type: Review

References (77)

1. P.Bonanni, C.Cohet, S.K.Kjaer, N.B.Latham, P.H.Lambert, K.Reisinger, R.M.Haupt. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. Vaccine 2010; 28: 4719- 30; PMID: 20451636; http://dx.doi.org/10.1016/j.vaccine.2010.04.070
2. E.Petrosky, J.A.Bocchini, Jr, S.Hariri, H.Chesson, C.R.Curtis, M.Saraiya, E.R.Unger, L.E.Markowitz, Centers for Disease C, Prevention. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015; 64: 300- 4; PMID: 25811679
3. Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant, Package Insert. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM11 1263.pdf
4. Human Papillomavirus Bivalent (types 16 and 18) Vaccine, Recombinant, Package Insert. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf
5. Human Papillomavirus 9-valent Vaccine, Recombinant, Package Insert. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM426457.pdf
6. T.Agorastos, K.Chatzigeorgiou, J.M.Brotherton, S.M.Garland. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 2009; 27: 7270- 81; PMID: 19799849; http://dx.doi.org/10.1016/j.vaccine.2009.09.097
7. K.K.Macartney, C.Chiu, M.Georgousakis, J.M.Brotherton. Safety of Human Papillomavirus Vaccines: A Review. Drug Saf 2013; PMID: 23637071
8. L.E.Markowitz, S.Hariri, E.R.Unger, M.Saraiya, S.D.Datta, E.F.Dunne. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010; 28: 4731- 7; PMID: 20188681; http://dx.doi.org/10.1016/j.vaccine.2010.02.019
9. M.Vichnin, P.Bonanni, N.P.Klein, S.M.Garland, S.L.Block, S.K.Kjaer, H.L.Sings, G.Perez, R.M.Haupt, A.J.Saah, et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J 2015; 34: 983- 91; PMID: 26107345; http://dx.doi.org/10.1097/INF.0000000000000793
10. P.M.Darden, D.M.Thompson, J.R.Roberts, J.J.Hale, C.Pope, M.Naifeh, R.M.Jacobson. Reasons for not vaccinating adolescents: National Immunization Survey of Teens, 2008–2010. Pediatrics 2013; 131: 645- 51; PMID: 23509163; http://dx.doi.org/10.1542/peds.2012-2384
11. S.Reagan-Steiner, D.Yankey, J.Jeyarajah, L.D.Elam-Evans, J.A.Singleton, C.R.Curtis, J.MacNeil, L.E.Markowitz, S.Stokley. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years–United States, 2014. MMWR Morb Mortal Wkly Rep 2015; 64: 784- 92; PMID: 26225476; http://dx.doi.org/10.15585/mmwr.mm6429a3
12. F.DeStefano. The Vaccine Safety Datalink project. PharmacoepidemiolDrug Saf 2001; 10: 403- 6; http://dx.doi.org/10.1002/pds.613
13. L.Sukumaran. Human Papillomavirus (HPV) Vaccine Safety Update. Presented at Advisory Committee on Immunization Practices Meeting October 2015. Available at: http://www.cdc.gov/vaccines/acip/meetings/slides-2015-10.html
14. B.A.Slade, L.Leidel, C.Vellozzi, E.J.Woo, W.Hua, A.Sutherland, H.S.Izurieta, R.Ball, N.Miller, M.M.Braun, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009; 302: 750- 7; PMID: 19690307; http://dx.doi.org/10.1001/jama.2009.1201
15. S.Stokley, J.Jeyarajah, D.Yankey, M.Cano, J.Gee, J.Roark, R.C.Curtis, L.Markowitz. Immunization Services Division NCfI, Respiratory Diseases CDC, et al. Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014–United States. MMWR Morb Mortal Wkly Rep 2014; 63: 620- 4; PMID: 25055185
16. S.C.C.Stokley, J.Jeyarajah, et al. Human Papillomavirus Vaccination Coverage Among Adolescent Girls, 2007–2012, and Postlicensure Vaccine Safety Monitoring, 2006–2013 — United States. MMWR Recomm Rep 2013; 62(29); 591- 595
17. Frequently asked questions about HPV Vaccine Safety. Available at: http://www.cdc.gov/vaccinesafety/vaccines/hpv/hpv-safety-faqs.html
18. Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (WONDER) search tool for the Vaccine Adverse Event Reporting System (VAERS). Available at: http://wonder.cdc.gov/vaers.html
19. J.Gee, A.Naleway, I.Shui, J.Baggs, R.Yin, R.Li, M.Kulldorff, E.Lewis, B.Fireman, M.F.Daley, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011; 29: 8279- 84; PMID: 21907257; http://dx.doi.org/10.1016/j.vaccine.2011.08.106
20. M.M.McNeil, E.S.Weintraub, J.Duffy, L.Sukumaran, S.J.Jacobsen, N.P.Klein, S.J.Hambidge, G.M.Lee, L.A.Jackson, S.A.Irving, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol 2015; PMID: 26452420
21. N.P.Klein, J.Hansen, C.Chao, C.Velicer, M.Emery, J.Slezak, N.Lewis, K.Deosaransingh, L.Sy, B.Ackerson, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012; 166: 1140- 8; PMID: 23027469; http://dx.doi.org/10.1001/archpediatrics.2012.1451
22. C.Della Corte, A.Carlucci, P.Francalanci, A.Alisi, V.Nobili. Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. Vaccine 2011; 29: 4654- 6; PMID: 21596082; http://dx.doi.org/10.1016/j.vaccine.2011.05.002
23. P.Pellegrino, C.Carnovale, V.Perrone, S.Antoniazzi, M.Pozzi, E.Clementi, S.Radice. Can HPV immunisation cause ADEM? Two case reports and literature review. Mult Scler 2014; 20: 762- 3; PMID: 23970503; http://dx.doi.org/10.1177/1352458513502114
24. B.Wildemann, S.Jarius, M.Hartmann, J.U.Regula, C.Hametner. Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology 2009; 72: 2132- 3; PMID: 19528522; http://dx.doi.org/10.1212/WNL.0b013e3181aa53bb
25. F.DeStefano, E.S.Weintraub, R.T.Chen. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2005; 64: 1317; PMID: 15832457
26. C.A.Siegrist. Autoimmune diseases after adolescent or adult immunization: what should we expect? CMAJ 2007; 177: 1352- 4; PMID: 18025425; http://dx.doi.org/10.1503/cmaj.071134
27. C.A.Siegrist, E.M.Lewis, J.Eskola, S.J.Evans, S.B.Black. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. PediatrInfectDisJ 2007; 26: 979- 84
28. S.J.Jacobsen, L.S.Sy, B.K.Ackerson, C.R.Chao, J.M.Slezak, T.C.Cheetham, H.S.Takhar, C.M.Velicer, J.Hansen, N.P.Klein. An unmasking phenomenon in an observational post-licensure safety study of adolescent girls and young women. Vaccine 2012; 30: 4585- 7; PMID: 22580356; http://dx.doi.org/10.1016/j.vaccine.2012.04.103
29. C.Chao, N.P.Klein, C.M.Velicer, L.S.Sy, J.M.Slezak, H.Takhar, B.Ackerson, T.C.Cheetham, J.Hansen, K.Deosaransingh, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. JInternMed 2012; 271: 193- 203
30. L.Grimaldi-Bensouda, D.Guillemot, B.Godeau, J.Benichou, C.Lebrun-Frenay, C.Papeix, P.Labauge, P.Berquin, A.Penfornis, P.Y.Benhamou, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med 2014; 275: 398- 408; PMID: 24206418; http://dx.doi.org/10.1111/joim.12155
31. L.Arnheim-Dahlstrom, B.Pasternak, H.Svanstrom, P.Sparen, A.Hviid. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013; 347: f5906; PMID: 24108159; http://dx.doi.org/10.1136/bmj.f5906
32. N.M.Scheller, H.Svanstrom, B.Pasternak, L.Arnheim-Dahlstrom, K.Sundstrom, K.Fink, A.Hviid. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 2015; 313: 54- 61; PMID: 25562266; http://dx.doi.org/10.1001/jama.2014.16946
33. D.T.Little, H.R.Ward. Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination. BMJ Case Rep 2012; 2012: ; PMID: 23035167
34. D.T.Little, H.R.Ward. Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice. J Investig Med High Impact Case Rep 2014; 2: ; PMID: 26425627
35. S.Dragojevic-Dikic, D.Marisavljevic, A.Mitrovic, S.Dikic, T.Jovanovic, S.Jankovic-Raznatovic. An immunological insight into premature ovarian failure (POF). Autoimmun Rev 2010; 9: 771- 4; PMID: 20601203; http://dx.doi.org/10.1016/j.autrev.2010.06.008
36. N.Santoro. Mechanisms of premature ovarian failure. Ann Endocrinol (Paris) 2003; 64: 87- 92; PMID: 12773939
37. G.Yan, D.Schoenfeld, C.Penney, K.Hurxthal, A.E.Taylor, D.Faustman. Identification of premature ovarian failure patients with underlying autoimmunity. J Womens Health Gend Based Med 2000; 9: 275- 87; PMID: 10787223; http://dx.doi.org/10.1089/152460900318461
38. N.M.Scheller, B.Pasternak, H.Svanstrom, A.Hviid. Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. JAMA 2014; 312: 187- 8; PMID: 25005658; http://dx.doi.org/10.1001/jama.2014.2198
39. A.L.Naleway, B.Crane, N.Smith, M.F.Daley, J.Donahue, J.Gee, S.K.Greene, T.Harrington, L.A.Jackson, N.P.Klein, et al. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink 2008–2011. Vaccine 2016; 34(1): 167- 71
40. W.K.Yih, S.K.Greene, L.Zichittella, M.Kulldorff, M.A.Baker, J.L.Jong, R.Gil-Prieto, M.R.Griffin, R.Jin, N.D.Lin, et al. Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females. Vaccine 2016; 34(1): 172- 8; PMID: 26549364
41. A.Sotiriadis, T.Dagklis, V.Siamanta, K.Chatzigeorgiou, T.Agorastos, L.S.Group. Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine. Arch Gynecol Obstet 2012; 285: 1719- 24; PMID: 22246478; http://dx.doi.org/10.1007/s00404-011-2208-z
42. European Medicines Agency recommends continued vaccination with Gardasil. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500011828.pdf
43. S.J.Hanley, E.Yoshioka, Y.Ito, R.Kishi. HPV vaccination crisis in Japan. Lancet 2015; 385: 2571; PMID: 26122153; http://dx.doi.org/10.1016/S0140-6736(15)61152-7
44. S.Richards, G.Chalkiadis, R.Lakshman, J.P.Buttery, N.W.Crawford. Complex regional pain syndrome following immunisation. Arch Dis Child 2012; 97: 913- 5; PMID: 22858647; http://dx.doi.org/10.1136/archdischild-2011-301307
45. C.C.M.Weinbaum. HPV Vaccination and Complex Regional Pain Syndrome: Lack of Evidence. EBioMed 2015; 2: 1014- 5; http://dx.doi.org/10.1016/j.ebiom.2015.08.030
46. L.Tomljenovic, S.Colafrancesco, C.Perricone, Y.Shoenfeld. Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the “Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants:” Case Report and Literature Review. J Investig Med High Impact Case Rep 2014; 2:2324709614527812; PMID: 26425598
47. L.S.Brinth, K.Pors, A.C.Theibel, J.Mehlsen. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine 2015; 33: 2602- 5; PMID: 25882168; http://dx.doi.org/10.1016/j.vaccine.2015.03.098
48. B.P.Grubb. Postural tachycardia syndrome. Circulation 2008; 117: 2814- 7; PMID: 18506020; http://dx.doi.org/10.1161/CIRCULATIONAHA.107.761643
49. R.Freeman, W.Wieling, F.B.Axelrod, D.G.Benditt, E.Benarroch, I.Biaggioni, W.P.Cheshire, T.Chelimsky, P.Cortelli, C.H.Gibbons, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011; 21: 69- 72; PMID: 21431947; http://dx.doi.org/10.1007/s10286-011-0119-5
50. Review concludes evidence does not support that HPV vaccines cause CRPS or POTS. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/11/WC500196352.pdf
51. Cancer vaccine girl died of malignant chest tumor. Medical News Today, 2009 Available at: http://wwwmedicalnewstodaycom/articles/165961php
52. Medical examiner: Girl's death not caused by HPV vaccination, Journal Sentinal, 2014. Available at: http://www.jsonline.com/news/health/medical-examiner-girls-death-not-caused-by-routine-vaccination-b99376029z1-280058462.html
53. N.L.McCarthy, J.Gee, L.Sukumaran, E.Weintraub, J.Duffy, E.O.Kharbanda, R.Baxter, S.Irving, J.King, M.F.Daley, et al. Vaccination and 30-day mortality risk in children, adolescents, and young adults. Pediatrics 2016; 137(3): 1- 8.
54. D.L.Hoyert, J.Xu. Deaths: preliminary data for 2011. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System 2012; 61: 1- 51
55. L.E.Markowitz, E.F.Dunne, M.Saraiya, H.W.Chesson, C.R.Curtis, J.Gee, J.A.Bocchini, Jr, E.R.Unger, Centers for Disease C, Prevention. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63: 1- 30; PMID: 25167164
56. S.M.Garland, K.A.Ault, S.A.Gall, J.Paavonen, H.L.Sings, K.L.Ciprero, A.Saah, D.Marino, D.Ryan, D.Radley, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009; 114: 1179- 88; http://dx.doi.org/10.1097/AOG.0b013e3181c2ca21
57. M.A.Goss, F.Lievano, K.M.Buchanan, M.M.Seminack, M.L.Cunningham, A.Dana. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine 2015; 33: 3422- 8; PMID: 25869893; http://dx.doi.org/10.1016/j.vaccine.2015.04.014
58. P.L.Moro, Y.Zheteyeva, P.Lewis, J.Shi, X.Yue, O.I.Museru, K.Broder. Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006–2013. Vaccine 2015; 33: 519- 22; PMID: 25500173; http://dx.doi.org/10.1016/j.vaccine.2014.11.047
59. M.J.Levin, A.B.Moscicki, L.Y.Song, T.Fenton, W.A.Meyer, 3rd, J.S.Read, E.L.Handelsman, B.Nowak, C.A.Sattler, A.Saah, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010; 55: 197- 204; PMID: 20574412; http://dx.doi.org/10.1097/QAI.0b013e3181de8d26
60. T.Wilkin, J.Y.Lee, S.Y.Lensing, E.A.Stier, S.E.Goldstone, J.M.Berry, N.Jay, D.Aboulafia, D.L.Cohn, M.H.Einstein, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202: 1246- 53; PMID: 20812850; http://dx.doi.org/10.1086/656320
61. E.M.Kojic, M.Kang, M.S.Cespedes, T.Umbleja, C.Godfrey, R.T.Allen, C.Firnhaber, B.Grinsztejn, J.M.Palefsky, J.Y.Webster-Cyriaque, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis 2014; 59: 127- 35; PMID: 24723284; http://dx.doi.org/10.1093/cid/ciu238
62. J.A.Kahn, J.Xu, B.G.Kapogiannis, B.Rudy, R.Gonin, N.Liu, C.M.Wilson, C.Worrell, K.E.Squires. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis 2013; 57: 735- 44; PMID: 23667266; http://dx.doi.org/10.1093/cid/cit319
63. V.Giacomet, F.Penagini, D.Trabattoni, A.Vigano, V.Rainone, G.Bernazzani, C.M.Bonardi, M.Clerici, G.Bedogni, G.V.Zuccotti. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine 2014; 32: 5657- 61; PMID: 25149430; http://dx.doi.org/10.1016/j.vaccine.2014.08.011
64. L.Toft, M.Storgaard, M.Muller, P.Sehr, J.Bonde, M.Tolstrup, L.Ostergaard, O.S.Sogaard. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis 2014; 209: 1165- 73; PMID: 24273179; http://dx.doi.org/10.1093/infdis/jit657
65. A.J.Wilcox, C.R.Weinberg, J.F.O'Connor, D.D.Baird, J.P.Schlatterer, R.E.Canfield, E.G.Armstrong, B.C.Nisula. Incidence of early loss of pregnancy. N Engl J Med 1988; 319: 189- 94; PMID: 3393170; http://dx.doi.org/10.1056/NEJM198807283190401
66. J.K.Iskander, E.R.Miller, R.T.Chen. The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety. PediatrAnn 2004; 33: 599- 606
67. F.Varricchio, J.Iskander, F.Destefano, R.Ball, R.Pless, M.M.Braun, R.T.Chen. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004; 23: 287- 94; PMID: 15071280; http://dx.doi.org/10.1097/00006454-200404000-00002
68. J.Baggs, J.Gee, E.Lewis, G.Fowler, P.Benson, T.Lieu, A.Naleway, N.P.Klein, R.Baxter, E.Belongia, et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics 2011; 127 Suppl 1: S45- S53; http://dx.doi.org/10.1542/peds.2010-1722H
69. T.A.Lieu, M.Kulldorff, R.L.Davis, E.M.Lewis, E.Weintraub, K.Yih, R.Yin, J.S.Brown, R.Platt. Real-time vaccine safety surveillance for the early detection of adverse events. MedCare 2007; 45: S89- S95
70. J.Woodcock. Another important step in FDA's journey towards enhanced safety through full-scale “active surveillance.” Available at: http://blogs.fda.gov/fdavoice/index.php/2014/12/another-important-step-in-fdas-journey-towards-enhanced-safety-through-full-scale-act ive-surveillance/
71. S.Findlay. Health Policy Brief: The FDA's Sentinel Initiative. Available at: http://healthaffairs.org/healthpolicybriefs/brief_pdfs/healthpolicybrief_139.pdf
72. Sentinel Initiative Public Workshop, 2016. Available at: http://healthpolicy.duke.edu/files/2016/03/8th-Annual-Sentinel-Public-Workshop-Slide-Deck-Edit.pdf
73. Approval Letter - Gardasil 9, 2014. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm426520.htm
74. S.E.Gollust, L.Attanasio, A.Dempsey, A.M.Benson, E.F.Fowler. Political and news media factors shaping public awareness of the HPV vaccine. Womens Health Issues 2013; 23: e143- 51; PMID: 23557851; http://dx.doi.org/10.1016/j.whi.2013.02.001
75. Institute of Medicine of the National Academies. Adverse events: evidence and causality Washington, DC: The National Academies Press; 2011
76. Global Advisory Committe On Vaccine safety Statement on Safety of HPV vaccines, 2015. Available at: http://www.who.int/vaccine_safety/committee/GACVS_HPV_statement_17Dec2015.pdf?ua=1. 2015
77. Global Advisory Committee on Vaccine Safety statement on the continued safety of HPV vaccination, 2014. Available at: http://www.who.int/vaccine_safety/committee/topics/hpv/GACVS_Statement_HPV_12_Mar_2014.pdf